Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Efsubaglutide Alfa

Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents

Shanghai Yinnuo Pharmaceutical Technology Co · Phase 1 · Recruiting · Enrollment 36

NCT07693426

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Efsubaglutide Alfa 5 mg QWn/rn/rn/rn/r
Efsubaglutide Alfa 10 mg QWn/rn/rn/rn/r
Efsubaglutide Alfa 20 mg QWn/rn/rn/rn/r
Efsubaglutide Alfa placebon/rn/rn/rn/r

Not shown

  • Efsubaglutide Alfa 5 mg QW: endpoint not reported
  • Efsubaglutide Alfa 10 mg QW: endpoint not reported
  • Efsubaglutide Alfa 20 mg QW: endpoint not reported
  • Efsubaglutide Alfa placebo: endpoint not reported